Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 14 minutes ago
- 2 min read
17/02/2026
Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD (Ref)
Sanofi and Teva announced positive results from the Phase 2b RELIEVE UCCD LTE/NCT05668013 study of duvakitug (anti-TL1A mAb) in patients with ulcerative colitis (UC) and Crohn’s disease (CD) who had initially responded to the induction phase
The Phase 2b study showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with UC and CD who had responded to the induction phase
UC: 58% (900 mg) and 47% (450 mg) of patients treated with duvakitug achieved the primary endpoint of clinical remission per the modified Mayo score (mMS)
CD: 55% (900 mg) and 41% (450 mg) of patients treated with duvakitug achieved the primary endpoint of endoscopic response as defined by the Simple Endoscopic Score for CD (SES-CD)
In both UC and CD, consistent benefits were observed across additional efficacy endpoints
Duvakitug was well tolerated and safety was consistent with the induction study
Detailed results from the study were to be presented at a forthcoming medical meeting
Nektar Therapeutics announced a research collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165 in multiple sclerosis (Ref)
Nektar Therapeutics announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L. Hauser to explore the potential role of NKTR-0165 (TNFR2 agonist) in several models of multiple sclerosis
The collaboration explored the potential role of TNFR2 agonism in reducing neurodegeneration and promoting neuroprotection and cell repair when neurons were exposed to patient-derived B cells
Under the agreement, the UCSF team conducted and funded all research efforts
Nektar supplied NKTR-0165 and retained all rights to its programs under the collaboration
